| Document |
Document Title |
|
WO/2011/073419A1 |
The present invention relates to a compound of formula (I) for its use for reversing or inhibiting multidrug resistance.
|
|
WO/2011/058776A1 |
Disclosed is a hollow structure carrier which has extended release properties and selectively delivers not only a carcinostatic agent but also a water-soluble substance having a high molecular weight to a desired target tissue (especiall...
|
|
WO/2011/031099A9 |
The present invention relates to an ursodeoxycholic acid-synthetic hydrotalcite-Eudragit hybrid, a pharmaceutical composition containing the same and a method for preparing the same. The ursodeoxycholic acid-synthetic hydrotalcite-Eudrag...
|
|
WO/2011/044523A2 |
Compositions and methods for treating obesity in a subject are described. Some embodiments provide methods for administering pharmaceutical formulations including biocompatible emulsifiers in an amount effective to treat obesity. In some...
|
|
WO/2011/022838A1 |
The invention provides, in part, polyhydroxylated bile acids for treating biliary disorders, for example, biliary disorders arising out of cholestasis or portal hypertesion. The invention also provides, in part, polyhydroxylated bile aci...
|
|
WO/2011/019821A2 |
Applicants have discovered a method for the stereoselective and regioselective synthesis of 3α-hydroxy, 3β-methyl-5α- pregnan-20-one (ganaxolone) comprising reacting 5α-pregnane-3,20-dione; with an organometallic methylating agent in...
|
|
WO/2011/019942A2 |
Synthetic cholesterylamine-linkers can include derivatives of cholesterol, cholesteryl, or sitosteryl coupled through the linker to an agent for delivery into cells. The cholesterylamines are thought to mimic cholesterol in the capacity ...
|
|
WO/2011/014661A2 |
Compounds of formula (I) as shown in the specification. Also disclosed are methods of using one of the compounds to lower the blood cholesterol level and treat cancer, atherosclerosis, diabetes, Alzheimer's disease, and corneal arcus.
|
|
WO/2011/002090A1 |
Disclosed is a method for producing a fatty acid lower alkyl ester, glycerin, and steryl glucoside by subjecting a fat or oil containing steryl glucoside in a dissolved state and a lower alcohol to a transesterification reaction, thereby...
|
|
WO/2010/146901A1 |
Provided is an alicyclic compound wherein one or two groups that contain cholic acid ester structures are bonded to an adamantane skeleton. Said alicyclic compound is useful as a dissolution inhibitor, a positive photoresist monomer used...
|
|
WO/2010/128472A1 |
Process for preparing glycocholic acid comprising the following steps: a) making a mixed anhydride of cholic acid through the suspension of cholic acid in acetone or in aqueous acetone in presence of a base, and subsequent reaction with ...
|
|
WO/2010/126276A2 |
The present invention relates to water-soluble sterol derivatives for lowering a cholesterol level and a method for preparing same. The method for preparing water-soluble sterol derivatives according to the present invention enables phyt...
|
|
WO/2010/126308A2 |
The present invention relates to water-soluble sterol derivatives for lowering a cholesterol level and to a method for preparing same. The method for preparing water-soluble sterol derivatives according to the present invention enables p...
|
|
WO/2010/114339A2 |
The present invention relates to water-soluble sterol derivatives capable of lowering cholesterol levels and a preparation method thereof. The preparation method of water-soluble sterol derivatives according to the present invention comp...
|
|
WO/2010/114320A2 |
The present invention relates to water-soluble sterol derivatives for lowering cholesterol levels and a method for producing the same. A method for producing water-soluble sterol derivatives for lowering cholesterol levels according to t...
|
|
WO/2010/100686A1 |
Disclosed is a cancer chemotherapeutic agent having reduced adverse side effects and excellent efficacy. The cancer chemotherapeutic agent comprises a combination of a cholestanol derivative represented by general formula (1) [wherein G ...
|
|
WO/2010/097810A2 |
The present invention relates to a synthetic method for the preparation of phytosteryl ferulate using ferulic acid and phytosterols (isolated from soybean oil deodorizer distillate) comprising of (a) acetylation of ferulic acid to feruli...
|
|
WO/2010/090859A2 |
Methods of using a 15-oxysterol, e.g., 15-ketocholestene (15-KE), 15-ketocholestane (15-KA), and/or 15-hydroxycholestene (15-HC), as a biomarker to monitor disease progression in multiple sclerosis (MS), and methods of treating secondary...
|
|
WO/2010/087339A1 |
Disclosed are an alicyclic compound in which a cholic acid ester structure-containing group is bound to an adamantane skeleton, method for manufacturing the same, composition containing the same, and resist pattern formation method using...
|
|
WO/2010/062369A2 |
Certain bile acids, including novel bile acids, and derivatives thereof can be used to inhibit the germination of C. difficile spores and/or the growth of C. difficile cells. The methods and compositions of the invention are useful for p...
|
|
WO/2010/058795A1 |
Provided is an antioxidant which is highly safe, inhibits oxidation of biological components, in particular, lipids and is usable as a drug, a food or a drink, a food additive, an external skin preparation and so on. A compound selected...
|
|
WO/2010/059853A1 |
The invention relates to compounds of Formula A: (A) or a salt, solvate, hydrate, or prodrug thereof. The compounds of Formula A are TGR5 modulators useful for the treatment of various diseases, including metabolic disease, inflammatory ...
|
|
WO/2010/059859A1 |
The invention relates to compounds of Formula (A): (A) or a salt, solvate, hydrate, or amino acid conjugate thereof. The compounds of formula A are TGR5 modulators useful for the prevention and treatment of disease.
|
|
WO/2010/056403A1 |
The present invention is directed to cationic lipid for the delivery of oligonucleotides and methods of modulating an expression of a targeted gene using the nanoparticle compositions. In particular, the invention relates to cholesterol ...
|
|
WO/2010/039267A1 |
An economical and environmentally friendly, "green", process for the continuous purification of triacylglycerol (TAG) is described using a powdered, granulated or extruded adsorbent, which can be used in either the chemical or physical r...
|
|
WO/2010/010228A1 |
The invention relates to an effective process for producing plant stanol by hydrogenating plant sterol in an organic solvent at a hydrogen pressure of 1-200 bar in the presence of a hydrogenation catalyst.
|
|
WO/2010/010227A1 |
The invention relates to an improved process for producing plant stanol by hydrogenating plant sterol in an organic solvent at a hydrogen pressure of 1-200 bar in the presence of a hydrogenation catalyst.
|
|
WO/2010/004193A1 |
The invention describes an overall process for the extraction of sterols, vitamin E, squalene and other plant-based hydrocarbons from deodorization distillates of plant oils. After an esterification of the free fatty acids, then a transe...
|
|
WO/2009/129596A9 |
A process for extraction of bioactive organic compounds from alkali extracts of Ascophyllum nodosum. Organic solvent extracts of A. nodosum namely; methanol, chloroform and ethylacetate, were found to alleviate salt induced stress in pla...
|
|
WO/2009/140225A2 |
The present invention relates to new glucocorticoid steroid modulators of glucocorticoid receptor, pharmaceutical compositions thereof, and methods of use thereof. Formula (I).
|
|
WO/2009/135352A1 |
A plum tree extract comprises 0.5-50 wt% squalene The plum tree extract mainly comes from fat-soluble portion and/or water-soluble portion of non-fruit part of plum tree A method for preparing the plum tree extract, comprises using super...
|
|
WO/2009/133401A1 |
The invention provides a synthetic route from sarsasapogenin to timosaponin BII a related compounds. A diketone intermediate is provided, which can advantageously used for in situ assembly of complex sugar moieties of the desired glycone...
|
|
WO/2009/124702A1 |
The invention relates to pharmaceutical compositions and forms of administration which contain compounds of general formula (I), and to contraceptive methods by administering these forms of administration. The invention further relates t...
|
|
WO/2009/120162A1 |
The invention relates to medicine, in particular to a biologically active substance and can be used for producing highly-effective medicinal and medicinal-and-prophylactic preparations for treating and preventing oncological diseases, an...
|
|
WO/2009/113935A1 |
There is disclosed a method for isolation and purification of phytosterols from tall oil pitch comprising the steps of: a) contacting the tall oil pitch with a solvent to form a tall oil solvent mixture; b) separating the tall oil pitch ...
|
|
WO/2009/110612A1 |
The purpose of the present invention is to find a new function for a component contained in germinated brown rice, and to provide an effective agent for preventing or ameliorating neuropathy or diabetic neuropathy, or a functional food p...
|
|
WO/2009/110235A1 |
Disclosed is a cancer chemotherapeutic agent having reduced side effects and excellent effectiveness. Specifically disclosed is a cancer chemotherapeutic agent which is obtained by combining a cholestanol derivative represented by genera...
|
|
WO/2009/106696A1 |
The invention telates to a processfor recovering sterols and fatty and/or resin acids from tall oil pitch, comprising the steps of: a) saponifying tall oil pitch to provide saponified tall oil pitch, b) drying the saponified pitch to obt...
|
|
WO/2009/108804A2 |
Provided are steroid analogues functionalized with polar substituents at the C3 and/or C20 positions of the steroid ring system that exhibit improved water solubility. Also provided are pharmaceutical compositions comprising the steroid ...
|
|
WO/2009/079921A1 |
The present invention relates to the pharmaceutical field and discloses cucurbitane triterpenoid saponins extracted from Momordica charantia, a pharmaceutical composition containing them and their preparation. The invention also disclose...
|
|
WO/2009/049370A1 |
The invention relates to novel compounds that have utility as inhibitors of heparan sulfate-binding proteins; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic...
|
|
WO/2009/029656A1 |
The present invention provides methods for inhibiting or blocking TGF-β activity in cells and/or tissues expressing TGF-β comprising, contacting cells and/or tissues expressing TGF-β with an amount of cholesterol or cholesterol deriva...
|
|
WO/2009/024103A2 |
The present invention relates to natural brassinosteroids of general formula (I), wherein R is CH2 or O-CH2 group, R2 is hydrogen or hydroxyl, R3 is hydroxyl, R24 is alkyl or alkenyl, which are selected from the group consisting of methy...
|
|
WO/2009/022477A1 |
[PROBLEMS] To provide a polymer wherein a biologically active substance is distributed uniformly at a high density. [MEANS FOR SOLVING PROBLEMS] The problems can be solved by selecting and using polynorbornene as the polymer.
|
|
WO/2009/011420A1 |
Disclosed is a medicinal agent comprising ursodeoxycholic acid or a pharmacologically acceptable salt thereof as an active ingredient, which can be act as a therapeutic agent for type-2 diabetes accompanied by fatty liver or liver dysfun...
|
|
WO/2009/007895A2 |
The present invention refers to a compound having anti-inflammatory and antiviral activity according to the following structural formula (I): wherein, R1 and R3 are selected from H, HO-, R5-O-, HCOO-, R5- COO-, -OOC-R6-COO-, p-toluene su...
|
|
WO/2009/003970A1 |
Provided herein are compounds, compositions and methods for decreasing NFkB DNA-binding activity in a patient comprising administering of a therapeutically effective amount of a compound or composition of the application to the patient t...
|
|
WO/2008/155998A1 |
Disclosed are: an antianxiety/antidepressant agent which has a satisfactory level of an antianxiety activity and/or an antidepressant activity; and a food or beverage comprising the antianxiety/antidepressant agent. Specifically disclose...
|
|
WO/2008/157635A2 |
Bile acids and related compositions and methods of synthesis and use. More specifically, deoxycholic acid and related compositions, said compositions being free of all moieties of animal origin and free of pyrogenic moieties.
|
|
WO/2008/149563A1 |
It is intended to provide a VDR ligand which does not induce hypercalcemia that is the side effect of a vitamin D3 preparation. A composition which contains lithocholic acid propionate, its salt or a solvate or prodrug of the same.
|
